BiotechTube
Home/Pipeline/Undisclosed Obesity Program

Undisclosed Obesity Program

Obesity

DiscoveryActive

Key Facts

Indication
Obesity
Phase
Discovery
Status
Active
Company
Syndya Therapeutics

About Syndya Therapeutics

Syndya Therapeutics is a private, pre-clinical stage biotech founded in 2019 and based in Schlieren, Switzerland. The company leverages a proprietary 3D combinatorial, phenotypic screening platform to discover novel drug combinations targeting complex diseases like MASH and obesity. Under the leadership of CEO Jan Lichtenberg, who has a strong background in phenotypic screening and company creation, Syndya is in stealth mode, actively seeking partners and investors to advance its pipeline. Its approach aims to tackle the multifactorial nature of metabolic diseases through innovative combination therapies.

View full company profile

Therapeutic Areas

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Obesity

Other Obesity Drugs

DrugCompanyPhase
LET003Harbour BioMedDiscovery
LET001Harbour BioMedDiscovery
RGT-075Regor TherapeuticsPhase 2b
Anti‑Obesity Oral DrugPremas BiotechPhase 1
Obesity Target Discovery CollaborationFauna BioTarget Discovery/Preclinical
GLP-1 variantsHeligenicsDiscovery
MYO Platform (Metabolic Disease)RenbioPre-clinical
Obesity Clinical TrialsIMA Clinical ResearchNot Applicable (Service)
KAYO-2000KayoTheraPreclinical
MVD-1 (SANA)Eolo PharmaPhase 1
GIP-neutralizing antibodyHelicore BiopharmaPre-clinical
Antral Gastroplasty / Endoscopic SleeveEndo-TAGSSPre-clinical